Kymera Therapeutics to Participate in Upcoming May Investor Conferences
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Kymera Therapeutics (NASDAQ: KYMR) will present at two investor conferences in May 2026 via fireside chats: Bank of America Healthcare Conference in Las Vegas on May 12, 2026 at 9:20 a.m. PT and RBC Capital Markets Global Healthcare Conference in New York on May 19, 2026 at 9:00 a.m. ET.
According to the company, live webcasts and archived replays will be available in the Investors > News and Events section at www.kymeratx.com.
Details
News Market Reaction – KYMR
On May 6, the day this news came out, KYMR closed 4.29% above the previous close.
Data tracked by StockTitan Argus for the May 6 session.
Key Figures
- Bank of America conference time
- 9:20 a.m. PT
- Bank of America 2026 Healthcare Conference on May 12
- RBC conference time
- 9:00 a.m. ET
- RBC Capital Markets 2026 Global Healthcare Conference on May 19
Historical Context
-
Presented new preclinical IBD data for KT-579 showing reduced disease activity.
-
Jeito Capital announced senior leadership hires with extensive life sciences experience.
-
Reported Q1 2026 results, strong cash position, Gilead milestone, and trial timelines.
-
Announced timing and webcast details for the Q1 2026 results release.
-
Received U.S. FDA Fast Track designation for KT-621 in moderate to severe asthma.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
oral small molecule degrader medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
WATERTOWN, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside chats at the following upcoming investor events:
- Bank of America 2026 Healthcare Conference in Las Vegas, NV on May 12 at 9:20 a.m. PT; and
- RBC Capital Markets 2026 Global Healthcare Conference in New York, NY on May 19 at 9:00 a.m. ET.
Live webcasts of the presentations will be available under “News and Events” in the Investors section of the Company’s website at www.kymeratx.com. Replays of the webcasts will be archived and available following the events.
About Kymera Therapeutics
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X or LinkedIn.
Investor Contact:
Justine Koenigsberg
investors@kymeratx.com
857-285-5300
Media Contact:
Matthew Henson
mhenson@kymeratx.com
857-285-5300
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.